NASDAQ
Lexaria Bioscience Corp. (LEXX)
♥ 611 Thanks from members
Lexaria Bioscience Corp. (LEXX) faces intense dual pressures: transitioning its DehydraTECH drug delivery tech toward high-value GLP-1/pharmaceutical markets while battling plunging legacy revenue, ongoing going-concern warnings, and a Nasdaq minimum bid price delisting notice.